Regarding your other question on HDL subtypes, it is not a question addressed in the Lancet genetic study as they tested SNPs that are associated with elevated HDL-C plasma level and not a spesific HDL subtype. Their data implies that raising HDL-C plasma level alone is not going to be clinically useful. Perhaps targeting a specific subtype or changing HDL molecule from pro-inflammatory HDL to anti-inflammatory HDL instead of raising HDL-C is the way to go, but this is far beyond my knowledge.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.